Now Enrolling

Working to Help in the Fight Against Advanced Gastric Cancer and Gastroesophageal Junction (GEJ) Cancer

The FIGHT (FGFR2 Inhibition in Gastric Cancer Therapy) Clinical Trial for Gastric & GEJ Cancer is a global Phase 3, randomized, double-blind, controlled study evaluating the efficacy of bemarituzumab in combination with the modified FOLFOX6 regimen (mFOLFOX6) in patients with FGFR2-selected, previously untreated advanced gastric or gastroesophageal (GEJ) cancer.

Bemarituzumab is an anti-fibroblast growth factor (FGF) receptor 2b (FGFR2b) humanized monoclonal antibody in clinical development as a targeted immune therapy for tumors that overexpress FGFR2b.

Bemarituzumab’s Mechanism of Action

Bemarituzumab’s mechanism of action has been explored preclinically, both in vitro and in vivo and has been shown to block tumor growth in 2 ways:

- **BLOCKS**
  - ligand binding and downstream signaling

- **ENHANCES**
  - antibody-dependent cell-mediated cytotoxicity (ADCC)
  - and recruitment of natural killer (NK) cells and T cells

FIGHT Gastric and GEJ Cancer Clinical Study

- The FIGHT Clinical Study for gastric and GEJ cancer is enrolling 548 patients at more than 200 study sites across the United States, Asia, Europe and Australia.
- Patients are eligible for enrollment based on FGFR2b protein overexpression and/or FGFR2 gene amplification, as determined by a proprietary IHC diagnostic assay and/or ctDNA blood assay.
- Bemarituzumab and/or chemotherapy treatment (mFOLFOX6) are administered via IV infusion every 2 weeks.

www.stomachcancertrial.com
www.ClinicalTrials.gov  Trial identifier: NCT03694522

Copyright 2018 Five Prime Therapeutics, Inc. All rights reserved.